EGF and Alzheimer disease: In the present study we assessed platelet APP, sAPPβ and serotonin in three different mouse models and human patients with AD; additionally, we evaluated platelet EGF levels in our human cohort, in order to evaluate whether these components are altered in AD and whether platelets are useful as peripheral biomarkers in AD.